BHCM
AVBP icon

Brevan Howard Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Brevan Howard Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
+8,823
New +$260K ﹤0.01% 1703
2026
Q1 		– Sell
-16,635
Closed -$335K – 2558
2025
Q4 		$335K Buy
+16,635
New +$346K ﹤0.01% 1312
2025
Q3 		– Sell
-9,592
Closed -$209K – 2343
2025
Q2 		$209K Buy
+9,592
New +$199K ﹤0.01% 1695

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brevan Howard Capital Management's AVBP Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 8,823 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #1703 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in AVBP as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in AVBP in Q2 2025 and has held it in 3 quarters since. The position peaked at $335K in Q4 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Brevan Howard Capital Management held 8,823 shares of ArriVent BioPharma worth $307K as of Q2 2026.
  • ArriVent BioPharma was a new Brevan Howard Capital Management position in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1703 holding.
  • Brevan Howard Capital Management first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's ArriVent BioPharma position peaked at $335K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.